Table 1 Clinical features of the patients whose samples were used for in vitro sequential glucocorticoid/imatinib treatment
From: GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells
Patient no. | Source | Disease phase | Resistance type |
|---|---|---|---|
1 | Bone marrow | Chronic | Non-mutated |
2 | Bone marrow | Accelerated | Non-mutated |
3 | Blood | Blastic | T315I mutation |
4 | Blood | Blastic | T315I mutation |
5 | Blood | Blastic | Non-mutated |
6 | Bone marrow | Accelerated | E255K mutation |
